Clear Creek Financial Management LLC Trims Position in Eli Lilly and Company $LLY

Clear Creek Financial Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,644 shares of the company’s stock after selling 251 shares during the quarter. Clear Creek Financial Management LLC’s holdings in Eli Lilly and Company were worth $3,620,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its holdings in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the period. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Wellington Management Group LLP raised its position in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at approximately $4,613,912,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of LLY opened at $845.55 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a market capitalization of $800.28 billion, a P/E ratio of 55.26, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The firm has a 50 day moving average of $738.69 and a 200 day moving average of $766.57. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on LLY. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $943.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.